/
Oncology
Cancers
75
Pipeline Programs↗
78
Active Trials↗
71
Companies Involved↗
Cancers is a moderately active landscape with 75 programs across 71 companies. The most active players are Mersana Therapeutics, Recursion Pharmaceuticals Inc., Vir Biotechnology, Inc.. 1 program is in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical17
Phase 119
Phase 238
Approved
No programs
Analysis
Modality Breakdown
77%
Small molecule
53 of 69 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 69 classified programs, each share of the total. Modality classified for 97% of 75 pipeline programs.
Analysis
Trial Status
234
clinical trials
Completed92 · 39%
Recruiting45 · 19%
Terminated35 · 15%
Active, not recruiting24 · 10%
Unknown status13 · 6%
Withdrawn11 · 5%
Other14 · 6%
Clinical Trials
Trial Activity
234 trials
Page 1 of 16
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)